Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fortschritte der Neurologie-Psychiatrie·2022
Same author

[Surgical Therapy for Lung Cancer: Why it Should be Performed in High Volume Centres].

Pneumologie (Stuttgart, Germany)·2020
Same author

Water safety plans for water supply utilities in China, Cuba, France, Morocco and Spain: costs, benefits, and enabling environment elements.

Urban water journal·2019
Same author

[Annual report 2018/2019 of the working group on informatics, digital pathology and biobanks].

Der Pathologe·2019
Same author

Structural flexibility versus rigidity of the aromatic unit of DNA ligands: binding of aza- and azoniastilbene derivatives to duplex and quadruplex DNA.

Organic & biomolecular chemistry·2019
Same author

[Annual report 2017/18 of the working group on informatics, digital pathology and biobanks].

Der Pathologe·2018

Related Experiment Videos

[Thymoma--incidence, classification and therapy].

C Stremmel1, S Dango, U Thiemann

  • 1Abteilung Thoraxchirurgie der Ludwig-Albert Universität Freiburg, Freiburg. christian.stremmel@uniklinik-freiburg.de

Deutsche Medizinische Wochenschrift (1946)
|September 28, 2007
PubMed
Summary

Thymomas are rare anterior mediastinum tumors. Surgical resection is the gold standard, with adjuvant radiation potentially improving survival for incomplete resections.

Related Experiment Videos

Area of Science:

  • Oncology
  • Thoracic Surgery

Context:

  • Thymomas constitute 50% of anterior mediastinum tumors.
  • Often associated with myasthenia gravis (10-15% of patients).
  • No specific early symptoms present.

Purpose:

  • To review current clinical practices and prognostic factors for thymomas.
  • To discuss the role of different treatment modalities.

Summary:

  • Thymomas are malignant tumors with significant recurrence rates and high mortality.
  • Masaoka and WHO classifications are crucial for prognosis.
  • Surgical resection is the primary treatment; adjuvant radiation may benefit incomplete resections.
  • Neoadjuvant chemotherapy with adjuvant radiotherapy improves outcomes in advanced stages (III/IV).

Impact:

  • Highlights the need for multimodal therapy in advanced thymomas.
  • Emphasizes the importance of both Masaoka and WHO classifications.
  • Underscores the limited role of adjuvant chemotherapy for thymomas.